Search


Jefferies London 2026: Intellia is currently in front of FDA for the potential approval of the first in vivo (in the body) CRISPR gene editing therapy - it is for hereditary angioedema
President & CEO John Leonard discusses the program and compares and contrasts it to more traditional medicines. He also provides an update on the company's transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) program. Coverage brought to you by
3 hours ago


The future of gene editing with Intellia’s CEO
Intellia Therapeutics CEO John Leonard on where he sees gene editing fitting into the practice of medicine.
Jun 23, 2023






.png)
